"We are seeing excellent growth in India, China"
"We are seeing excellent growth in India,China"
-Dr Poonam Taneja, director, Global LCM Sales, and Asia and
Latin America Distributor Sales, MDS Analytical Technologies
US-based MDS Analytical
Technologies is a leading global supplier of life sciences tools that
comprises two main channel brands, MDS Sciex and Molecular Devices. MDS
Sciex offers proven market leadership in mass spectrometry and
Molecular Devices sets the standard for high-performance bioanalytical
The company has recently
entered into an agreement to sell MDS Analytical Technologies to
Danaher Corporation. Dr Poonam Taneja shares with BioSpectrum the
company's progress in the last one year and plans for 2010, and beyond.
How do you rate your
business performance in the fiscal year 2009, especially given the
difficult economic environment?
We have had high double digit growth in revenue last year with
Molecular Devices products in India. Spinco Biotech is the exclusive
distributor for all Molecular Devices products for India. Spinco
Biotech for the second year in succession has proved to be a valuable
channel partner particularly for our multimode microplate readers,
and drug discovery systems. A major part of this growth came from CROs
and Indian pharma companies for our drug screening technology platforms.
How does Molecular
Devices plan to sustain and exceed such enviable growth rates?
As pharma companies in India continue to invest in novel drug discovery
programs, we expect to see a growing need for highend
drug discovery technologies. We believe researchers in India will adopt
high content cellular imaging systems given the research progressing in
these areas and our successes in rest of the world. This technology
provides scientists with information on how potential therapeutics
effect cells and cellular processes. Moreover, as government funding
expands, we expect the revenue from microplate readers and washers to
bring in additional level of growth.
What changes can we
expect for Molecular Devices once the acquisition by Danaher
Corporation is completed?
As you are aware, Danaher Corporation has agreed to purchase Molecular
Devices from MDS. Danaher, based in Washington, US, is a successful,
publiclytraded company with more than 50,000 employees, over $12
billion (about Rs 56,000 crore) revenue in 2008, and comprises of four
market segments: medical technologies, professional instrumentation,
industrial technologies, and tools and components. Danaher sees this
acquisition as a logical extension of its long-term strategy to expand
in the life sciences instrumentation markets. They are excited about
the Molecular Devices technologies, the people and the opportunity to
build an even stronger and more successful business.
Danaher has a reputation for acquiring solid companies in attractive
markets, with strong brands and bright futures, and they have made over
50 successful acquisitions since 2002. It is their intention to further
the capabilities of the Molecular Devices instruments by fostering the
innovation of new products.
What new products will
Molecular Devices be launching in 2010?
Molecular Devices will continue to offer innovative solutions for life
sciences research and drug discovery. We have had several new product
enhancements throughout the previous year. Recently, we expanded our
SpectraMax Microplate Reader platform with the launch of the faster
throughput SpectraMax L Luminometer and the new upgradeable SpectraMax
M3 and M4 multimode readers.
Which technologies will
be most exciting for the research market in India?
All of our leading technologies such as microplate multi-mode readers
and washers, high-end technologies including Flipr Tetra for drug
discovery screening, the high content live cell screening systems for
cell-based assays and automated electrophysiology systems for ion
channel screening, are directly relevant to the rapidly expanding
biotechnology, research, and clinical markets in India.
Describe your progress in
the drug discovery market in India?
We have several drug discovery systems installed in various pharma
companies throughout India, and have additional forthcoming purchase
orders from government laboratories, biotechnology and pharma
companies. Our distributor partner, Spinco Biotech, has been successful
in selling and supporting our drug discovery systems such as
FlexStation, Flipr Tetra, Threshold and Multi-mode Micro Plate readers.
What fuels the market for
drug discovery products in India?
Most of the growth for drug discovery products in India is from CROs
and pharma/ biotech industries from their domestic and international
projects for the drug discovery program. Investors worldwide are
recognizing the need for investing in this growing economy.
Which countries in Asia
are providing better growth rate for Molecular Devices?
We are seeing an excellent growth throughout Asia, especially in India
and China. We have instrument demonstration facilities in India, China,
Singapore and Australia, and provide hands-on applications workshops
and seminars throughout Asia Pacific for all of our products. We have
established a regional team of Molecular Devices technical and service
specialists to ensure that we are providing complete support to our
customers. We see India as a high growth market. We view the entire
Asia Pacific as the growth market.
We have established a regional dedicated team of Molecular Devices
technical and service specialists to work with our distributor partners
and support the customers in India. We regularly conduct technical
hands-on workshops, user meetings and research seminars throughout this
region. Our ongoing collaborations with customers in India have further
facilitated our understanding of their research applications and needs.
For this year, what is
the company's strategy for growth?
Molecular Devices will continue the company to grow, both organically
through development of innovative products and, acquisition and
licensing of novel technologies.
Jahanara Parveen in